• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

拟钙剂R-568及其对映体S-568对大鼠的急性心血管效应

Acute cardiovascular effects of the calcimimetic R-568 and its enantiomer S-568 in rats.

作者信息

Nakagawa Kumiko, Parekh Niru, Koleganova Nadezda, Ritz Eberhard, Schaefer Franz, Schmitt Claus Peter

机构信息

Division of Paediatric Nephrology, Centre for Paediatric and Adolescent Medicine, University of Heidelberg, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany.

出版信息

Pediatr Nephrol. 2009 Jul;24(7):1385-9. doi: 10.1007/s00467-009-1153-6. Epub 2009 Mar 12.

DOI:10.1007/s00467-009-1153-6
PMID:19280225
Abstract

Calcimimetics increase the sensitivity of the calcium sensing receptor (CaSR) to calcium ions (Ca(2+)) and allow for efficient control of uraemic hyperparathyroidism. Recent studies suggested an additional blood pressure-lowering action, the underlying mechanisms are as yet unknown. We infused R-568 and its enantiomer S-568, which has little activity at the CaSR, in anaesthetized rats. Mean arterial blood pressure (MAP) and heart rate (HR) were measured in the femoral artery; renal blood flow (RBF) and mesenteric blood flow (MBF) were measured locally. Infusion of R-568 at 0.7 mg/kg per 10 min into the femoral vein, a dose known to reduce levels of parathyroid hormone (PTH) and Ca(2+) in plasma, did not affect blood pressure or heart rate. Infusion of 2.1 mg/kg per 3 min of R-568 and S-568 into the femoral vein significantly reduced MAP by 26 +/- 4.5 and 23.7 +/- 3.1% and HR by 7.8 +/- 2.9 and 5.8 +/- 2.0%, respectively. Intra-arterial infusions of R-568 increased blood flow in a dose-dependent fashion. At plasma concentrations of 70 micromol/l R-568 and S-568 increased RBF by 17 +/- 3 and 15 +/- 3% and MBF by 28 +/- 5 and 29 +/- 5%. The effects on blood flow were greater in the mesenteric artery than in the renal artery, but not different between both compounds.The calcimimetic R-568 exerts acute, CaSR-independent, hypotensive effects via vasodilation and negative chronotropy at concentrations exceeding those required for modulation of PTH secretion.

摘要

钙敏感受体激动剂可提高钙敏感受体(CaSR)对钙离子(Ca(2+))的敏感性,从而有效控制尿毒症性甲状旁腺功能亢进。最近的研究表明其具有额外的降压作用,但其潜在机制尚不清楚。我们在麻醉大鼠中输注R-568及其对映体S-568,后者对CaSR几乎没有活性。在股动脉测量平均动脉血压(MAP)和心率(HR);局部测量肾血流量(RBF)和肠系膜血流量(MBF)。以每10分钟0.7mg/kg的剂量将R-568输注到股静脉中,该剂量已知可降低血浆中甲状旁腺激素(PTH)和Ca(2+)的水平,但不影响血压或心率。以每3分钟2.1mg/kg的剂量将R-568和S-568输注到股静脉中,可使MAP分别显著降低26±4.5%和23.7±3.1%,使HR分别降低7.8±2.9%和5.8±2.0%。动脉内输注R-568可使血流量呈剂量依赖性增加。在血浆浓度为70μmol/l时,R-568和S-568使RBF分别增加17±3%和15±3%,使MBF分别增加28±5%和29±5%。对肠系膜动脉血流量的影响大于肾动脉,但两种化合物之间没有差异。钙敏感受体激动剂R-568在浓度超过调节PTH分泌所需浓度时,通过血管舒张和负性变时作用发挥急性、不依赖CaSR的降压作用。

相似文献

1
Acute cardiovascular effects of the calcimimetic R-568 and its enantiomer S-568 in rats.拟钙剂R-568及其对映体S-568对大鼠的急性心血管效应
Pediatr Nephrol. 2009 Jul;24(7):1385-9. doi: 10.1007/s00467-009-1153-6. Epub 2009 Mar 12.
2
Calcimimetic R-568 and its enantiomer S-568 increase nitric oxide release in human endothelial cells.钙敏感受体激动剂 R-568 及其对映异构体 S-568 增加人内皮细胞一氧化氮的释放。
PLoS One. 2012;7(1):e30682. doi: 10.1371/journal.pone.0030682. Epub 2012 Jan 25.
3
Pharmacological activity of calcimimetic NPS R-568 administered intravenously in rats: dose dependency.大鼠静脉注射拟钙剂NPS R-568的药理活性:剂量依赖性
Pharmacol Rep. 2006 Jul-Aug;58(4):533-9.
4
Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion.发现一种具有不同甲状旁腺激素和降钙素分泌作用的拟钙剂。
J Pharmacol Exp Ther. 2011 Jun;337(3):681-91. doi: 10.1124/jpet.110.178681. Epub 2011 Mar 21.
5
Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency.拟钙剂化合物上调慢性肾功能不全大鼠甲状旁腺中降低的钙敏感受体表达水平。
J Am Soc Nephrol. 2004 Oct;15(10):2579-87. doi: 10.1097/01.ASN.0000141016.20133.33.
6
Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.参与细胞内钙(Ca2+)调节的功能蛋白在药物研发中的应用:细胞外钙受体及通过拟钙剂控制继发性甲状旁腺功能亢进的创新医学方法。
J Pharmacol Sci. 2005 Mar;97(3):355-60. doi: 10.1254/jphs.fmj04007x6. Epub 2005 Mar 17.
7
Calcimimetics increase CaSR expression and reduce mineralization in vascular smooth muscle cells: mechanisms of action.钙敏感受体激动剂增加血管平滑肌细胞中钙敏感受体的表达并减少矿化作用:作用机制。
Cardiovasc Res. 2014 Feb 1;101(2):256-65. doi: 10.1093/cvr/cvt249. Epub 2013 Nov 11.
8
[Calcimimetics, mechanisms of action and therapeutic applications].[拟钙剂、作用机制及治疗应用]
Presse Med. 2005 Sep 10;34(15):1095-100. doi: 10.1016/s0755-4982(05)84125-9.
9
Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca(2+) receptor in rats.拟钙剂化合物NPS R-568刺激大鼠降钙素分泌,但选择性作用于甲状旁腺Ca(2+)受体。
J Pharmacol Exp Ther. 1999 Aug;290(2):480-6.
10
NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium.NPS R - 568:一种II型拟钙剂化合物,作用于大鼠甲状旁腺细胞钙受体,以降低血浆甲状旁腺激素和钙水平。
J Pharmacol Exp Ther. 1999 Aug;290(2):473-9.

引用本文的文献

1
Role of the calcium-sensing receptor in regulating vascular function.钙敏感受体在调节血管功能中的作用。
J Cell Commun Signal. 2025 Feb 5;19(1):e70004. doi: 10.1002/ccs3.70004. eCollection 2025 Mar.
2
International Union of Basic and Clinical Pharmacology. CVIII. Calcium-Sensing Receptor Nomenclature, Pharmacology, and Function.国际基础和临床药理学联合会。CVIII. 钙敏感受体命名、药理学和功能。
Pharmacol Rev. 2020 Jul;72(3):558-604. doi: 10.1124/pr.119.018531.
3
CaSR participates in the regulation of vascular tension in the mesentery of hypertensive rats via the PLC‑IP3/AC‑V/cAMP/RAS pathway.

本文引用的文献

1
Calcimimetic R-568 or calcitriol: equally beneficial on progression of renal damage in subtotally nephrectomized rats.拟钙剂R-568或骨化三醇:对肾次全切除大鼠肾损伤进展的益处相同。
Am J Physiol Renal Physiol. 2008 Apr;294(4):F748-57. doi: 10.1152/ajprenal.00220.2007. Epub 2008 Jan 16.
2
Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.用于慢性肾病患者继发性甲状旁腺功能亢进的拟钙剂
Cochrane Database Syst Rev. 2006 Oct 18(4):CD006254. doi: 10.1002/14651858.CD006254.
3
Pharmacological activity of calcimimetic NPS R-568 administered intravenously in rats: dose dependency.
钙敏感受体(CaSR)通过 PLC-IP3/AC-V/cAMP/RAS 通路参与高血压大鼠肠系膜血管张力的调节。
Mol Med Rep. 2019 Nov;20(5):4433-4448. doi: 10.3892/mmr.2019.10620. Epub 2019 Aug 27.
4
Calcimimetic R568 reduced the blood pressure and improved aortic remodeling in spontaneously hypertensive rats by inhibiting local renin-angiotensin system activity.拟钙剂R568通过抑制局部肾素-血管紧张素系统活性降低自发性高血压大鼠的血压并改善主动脉重塑。
Exp Ther Med. 2018 Nov;16(5):4089-4099. doi: 10.3892/etm.2018.6734. Epub 2018 Sep 13.
5
Calcimimetic R-568 vasodilatory effect on mesenteric vascular beds from normotensive (WKY) and spontaneously hypertensive (SHR) rats. Potential involvement of vascular smooth muscle cells (vSMCs).钙敏感受体激动剂 R-568 对正常血压(WKY)和自发性高血压(SHR)大鼠肠系膜血管床的血管舒张作用。血管平滑肌细胞(vSMCs)的潜在参与。
PLoS One. 2018 Aug 9;13(8):e0202354. doi: 10.1371/journal.pone.0202354. eCollection 2018.
6
The vascular Ca2+-sensing receptor regulates blood vessel tone and blood pressure.血管钙敏感受体调节血管张力和血压。
Am J Physiol Cell Physiol. 2016 Feb 1;310(3):C193-204. doi: 10.1152/ajpcell.00248.2015. Epub 2015 Nov 4.
7
Calcimimetic R-568 and its enantiomer S-568 increase nitric oxide release in human endothelial cells.钙敏感受体激动剂 R-568 及其对映异构体 S-568 增加人内皮细胞一氧化氮的释放。
PLoS One. 2012;7(1):e30682. doi: 10.1371/journal.pone.0030682. Epub 2012 Jan 25.
8
New concepts in calcium-sensing receptor pharmacology and signalling.钙敏感受体药理学和信号转导的新概念。
Br J Pharmacol. 2012 Jan;165(1):35-48. doi: 10.1111/j.1476-5381.2011.01511.x.
9
The calcium-sensing receptor and calcimimetics in blood pressure modulation.钙敏感受体及其调节剂在血压调节中的作用。
Br J Pharmacol. 2011 Oct;164(3):884-93. doi: 10.1111/j.1476-5381.2011.01317.x.
10
Vascular actions of calcimimetics: role of Ca²(+) -sensing receptors versus Ca²(+) influx through L-type Ca²(+) channels.钙敏感受体与 L 型钙通道钙内流在拟钙剂血管作用中的比较
Br J Pharmacol. 2011 Feb;162(3):749-62. doi: 10.1111/j.1476-5381.2010.01079.x.
大鼠静脉注射拟钙剂NPS R-568的药理活性:剂量依赖性
Pharmacol Rep. 2006 Jul-Aug;58(4):533-9.
4
Extracellular calcium sensing in rat aortic vascular smooth muscle cells.大鼠主动脉血管平滑肌细胞中的细胞外钙感知
Biochem Biophys Res Commun. 2006 Oct 6;348(4):1215-23. doi: 10.1016/j.bbrc.2006.07.192. Epub 2006 Aug 7.
5
Acute blood pressure effects and chronic hypotensive action of calcimimetics in uremic rats.拟钙剂对尿毒症大鼠的急性血压影响及慢性降压作用
J Am Soc Nephrol. 2006 Mar;17(3):655-62. doi: 10.1681/ASN.2005090914. Epub 2006 Jan 18.
6
Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism.拟钙剂盐酸西那卡塞对继发性甲状旁腺功能亢进患者心血管疾病、骨折及健康相关生活质量的影响。
Kidney Int. 2005 Oct;68(4):1793-800. doi: 10.1111/j.1523-1755.2005.00596.x.
7
Evidence in favor of a calcium-sensing receptor in arterial endothelial cells: studies with calindol and Calhex 231.支持动脉内皮细胞中钙敏感受体的证据:使用卡林多和Calhex 231的研究
Circ Res. 2005 Aug 19;97(4):391-8. doi: 10.1161/01.RES.0000178787.59594.a0. Epub 2005 Jul 21.
8
Calcimimetic NPS R-568 induces hypotensive effect in spontaneously hypertensive rats.
Am J Hypertens. 2005 Mar;18(3):364-71. doi: 10.1016/j.amjhyper.2004.10.019.
9
Evidence for a functional calcium-sensing receptor that modulates myogenic tone in rat subcutaneous small arteries.大鼠皮下小动脉中存在调节肌源性张力的功能性钙敏感受体的证据。
Am J Physiol Heart Circ Physiol. 2005 Apr;288(4):H1756-62. doi: 10.1152/ajpheart.00739.2004. Epub 2004 Dec 2.
10
Calcimimetic and calcilytic drugs: just for parathyroid cells?拟钙剂和钙敏化药物:仅作用于甲状旁腺细胞吗?
Cell Calcium. 2004 Mar;35(3):283-9. doi: 10.1016/j.ceca.2003.10.020.